B tier · viable
Liothyronine is an FDA-approved thyroid hormone with a clear regulatory basis for hypothyroidism replacement, TSH suppression and diagnostic use, but randomised evidence that adding it to levothyroxine improves patient outcomes has been largely negative, and its label carries a boxed warning against weight-loss use.
liothyronine
Liothyronine is synthetic triiodothyronine, approved as replacement or supplemental therapy in hypothyroidism, for TSH suppression in well-differentiated thyroid cancer, and as a diagnostic agent in thyroid suppression tests. Randomised trials of adding liothyronine to levothyroxine have generally not shown improvement in quality of life or tissue markers.
the explanation
Liothyronine is the fast-acting form of thyroid hormone, prescribed when the thyroid is underactive. Its label carries the FDA's strongest warning that thyroid hormones must not be used for weight loss.
regulatory status
FDA-approved with BOXED WARNING
Approved for hypothyroidism replacement (primary, secondary, tertiary), TSH suppression as an adjunct to surgery and radioiodine in well-differentiated thyroid cancer, and as a diagnostic agent in suppression tests for suspected hyperthyroidism. The label carries a boxed warning that thyroid hormones must not be used for obesity or weight loss.
how it works · proposed mechanism
Liothyronine is exogenous triiodothyronine, the ligand that directly activates nuclear thyroid hormone receptors.
Direct nuclear receptor binding
T3 binds thyroid hormone receptor alpha and beta isoforms, which act as ligand-dependent transcription factors on thyroid response elements. This regulates basal metabolic rate, protein synthesis and substrate utilisation across essentially all tissues.
Bypasses deiodination
Levothyroxine is a prohormone requiring peripheral deiodinase conversion to T3; liothyronine is already active. This gives faster onset but removes the physiological buffering that deiodinase regulation normally provides.
Cardiac amplification
Thyroid hormone receptors in cardiac tissue upregulate beta-adrenergic responsiveness and contractile protein expression. The label warns that overtreatment increases heart rate, cardiac wall thickness and contractility, and may precipitate angina or arrhythmias.
what’s reported
evidence shape
5 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
The FDA label states in a boxed warning that thyroid hormones, including liothyronine, must not be used for obesity or weight loss, and that in euthyroid people doses within normal hormonal requirements are ineffective for weight reduction while larger doses risk serious or life-threatening toxicity. The label goes further and singles out combination with sympathomimetic amines as amplifying that risk — so the approved-indication evidence graded here transfers to hypothyroidism replacement and to nothing about the fat-loss use it is sold for.
key published findings
- Regulatory (boxed warning, verbatim): 'Thyroid hormones, including CYTOMEL, should not be used for the treatment of obesity or for weight loss,' with larger doses capable of causing 'serious or even life-threatening manifestations of toxicity.'
- Regulatory (label): in patients with normal thyroid function, doses within the range of normal hormonal requirements are ineffective for weight reduction, and larger doses risk serious toxicity particularly when combined with sympathomimetic amines.
- Human trial (randomised, double-blind, placebo-controlled): the LEVOLIO study randomised 141 totally thyroidectomised subjects (70 combination, 71 placebo) over 24 weeks; neither SHBG and other tissue markers nor quality of life differed significantly between groups.
- Human trial (LEVOLIO, same study): the combination arm achieved the intended biochemical shift, with fT3/fT4 ratio 0.32 ± 0.08 versus 0.26 ± 0.05 on levothyroxine plus placebo (P < .001), yet required more frequent dose adjustments (54% versus 25%, P < .001) — biochemical change without clinical benefit.
- Human trial (LEVOLIO, genetics): DIO2 and MCT10 polymorphisms, the leading candidate explanation for why some patients might benefit from added T3, showed no influence on outcomes.
limitations of the evidence
- Combination-therapy trials have been heterogeneous in population, duration and outcome measure, and most are shorter than a year, so durable effects remain unresolved.
- The strongest recent randomised evidence is in thyroidectomised subjects, who lack residual thyroid function and may not represent typical hypothyroid patients.
- There is no randomised evidence base at all for liothyronine in euthyroid people, because such use is explicitly warned against rather than studied.
documented safety signals
- BOXED WARNING: thyroid hormones must not be used for obesity or weight loss; larger doses may produce serious or life-threatening toxicity.
- The label specifically warns that toxicity risk is amplified when thyroid hormone is combined with sympathomimetic amines — the combination described in clenbuterol poison-centre reports.
- Overtreatment increases heart rate, cardiac wall thickness and contractility and may precipitate angina or arrhythmias, with particular risk in elderly patients and those with cardiovascular disease.
- Atrial fibrillation is a recognised consequence of thyrotoxicosis, whether endogenous or iatrogenic.
- Excess thyroid hormone accelerates bone resorption and is associated with reduced bone mineral density, particularly in postmenopausal women.
- Because liothyronine bypasses deiodinase regulation, serum T3 peaks are higher and less buffered than with levothyroxine, narrowing the margin before cardiac effects.
- Signs of overtreatment include palpitations, tremor, heat intolerance, weight loss, anxiety, insomnia and diarrhoea; these overlap with the effects users of stimulant fat-loss products may misattribute to benefit.
- Abrupt changes in thyroid hormone exposure can precipitate adrenal crisis in patients with untreated adrenal insufficiency.
- Interactions with anticoagulants, digitalis glycosides and antidiabetic agents require monitoring; absorption is affected by numerous binding agents.
identity
| full name | Liothyronine sodium (triiodothyronine, T3) |
| category | Thyroid & Stimulant |
| modality | small molecule |
| formula | C15H12I3NO4 |
| molar mass | 650.97 g/mol |
| cas | 6893-02-3 |
| half-life | ~2.5 days (biological) |
laboratory handling
| storage | Marketed tablets are stored at controlled room temperature in tight, light-resistant containers per the approved label; thyroid hormone potency is degraded by heat, light and humidity. |
| solubility | Liothyronine free acid is poorly water-soluble; the marketed sodium salt is substantially more soluble, and the molecule is amphoteric with both amino and carboxylic acid groups. |
| co-studied with | The label's euthyroid-patient warning names sympathomimetic amines specifically as amplifying thyroid hormone toxicity risk, which is the documented hazard behind combined thyroid-plus-beta-agonist use reported in poison-centre clenbuterol cases. This is recorded as a labelled hazard, not as a protocol. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
5 citedDailyMed / US FDA · 2023 · official
US FDA Drugs@FDA · 2024 · official
StatPearls, NCBI Bookshelf · 2024 · review
US DEA Diversion Control Division · 2013 · review
European Journal of Endocrinology · 2024 · randomized
others in Thyroid & Stimulant